MARKET

CBMG

CBMG

Cellular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.70
-0.75
-5.19%
After Hours: 13.68 -0.02 -0.15% 16:00 05/27 EDT
OPEN
14.56
PREV CLOSE
14.45
HIGH
14.56
LOW
13.62
VOLUME
113.42K
TURNOVER
--
52 WEEK HIGH
18.99
52 WEEK LOW
10.98
MARKET CAP
265.66M
P/E (TTM)
-5.0593
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CBMG stock price target is 19.00 with a high estimate of 19.00 and a low estimate of 19.00.

EPS

CBMG News

More
Hedge Funds Are Warming Up To Cellular Biomedicine Group, Inc. (CBMG)
Insider Monkey · 7h ago
Cellular Biomedicine Group (CBMG) Announces 2020 Annual Meeting of Stockholders
PR Newswire · 1d ago
Edited Transcript of CBMG earnings conference call or presentation 6-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 3d ago
Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 17:18
Cellular Biomedicine Group Inc (CBMG) Q1 2020 Earnings Call Transcript
Motley Fool · 05/07 20:31
Cellular Biomedicine EPS beats by $0.16
Cellular Biomedicine (NASDAQ:CBMG): Q1 GAAP EPS of -$0.60 beats by $0.16. Cash, equivalents and restricted cash of $21.6M (+40.3% Q/Q) Press Release
seekingalpha · 05/07 02:01
Cellular Biomedicine Group Reports Q1 2020 Financial Results and Business Highlights
PR Newswire · 05/06 21:16
Cellular Biomedicine Gr Q1 EPS $(0.600) Down From $(0.510) YoY
Cellular Biomedicine Gr (NASDAQ:CBMG) reported quarterly losses of $(0.600) per share. This is a 17.65 percent decrease over losses of $(0.510) per share from the same period last year.
Benzinga · 05/06 20:50

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Symbol
Price
%Change

About CBMG

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases.
More

Webull offers kinds of Cellular Biomedicine Group Inc stock information, including NASDAQ:CBMG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBMG stock news, and many more online research tools to help you make informed decisions.